Sulbutiamine Reference

Reference summary

Sulbutiamine is a lipophilic synthetic thiamine dimer that crosses the blood-brain barrier more readily than thiamine and elevates brain thiamine pyrophosphate. French clinical literature in functional asthenia, most notably the Tiev 1999 (Rev Med Interne) and Loo 1992 trials, reports modest short-course improvement on subjective fatigue endpoints, with effect sizes that decay quickly on continued use as tolerance builds. Smaller trials in postinfectious fatigue and chemotherapy-related asthenia are mixed. Hypomania, irritability, and withdrawal-like rebound have been reported in case literature, and the French label limits course length accordingly.

Regulatory and posture

Categories

Nootropic

Aliases

Arcalion, Bisibutiamine, Enerion, Isobutyryl thiamine disulfide

Evidence posture

human - Not FDA-approved in the US. French non-US approval for functional asthenia. Tolerance reportedly builds quickly with daily use; the French label caps course length. Hypomania and irritability case reports are concerning in users with a bipolar-spectrum history.

Regulatory status

No FDA-approved sulbutiamine drug label in the US. Approved in France (Arcalion) and several non-US markets (notably Vietnam and parts of West Africa) for functional asthenia. Sold as a dietary supplement in some markets, including the US, where it has no FDA-approved drug label.

Content review status

research reference